Literature DB >> 28120524

Sizing clinical trials when comparing bivariate time-to-event outcomes.

Tomoyuki Sugimoto1, Toshimitsu Hamasaki2, Scott R Evans3, Takashi Sozu4.   

Abstract

Clinical trials with multiple primary time-to-event outcomes are common. Use of multiple endpoints creates challenges in the evaluation of power and the calculation of sample size during trial design particularly for time-to-event outcomes. We present methods for calculating the power and sample size for randomized superiority clinical trials with two correlated time-to-event outcomes. We do this for independent and dependent censoring for three censoring scenarios: (i) the two events are non-fatal; (ii) one event is fatal (semi-competing risk); and (iii) both are fatal (competing risk). We derive the bivariate log-rank test in all three censoring scenarios and investigate the behavior of power and the required sample sizes. Separate evaluations are conducted for two inferential goals, evaluation of whether the test intervention is superior to the control on: (1) all of the endpoints (multiple co-primary) or (2) at least one endpoint (multiple primary).
Copyright © 2017 John Wiley & Sons, Ltd. Copyright © 2017 John Wiley & Sons, Ltd.

Entities:  

Keywords:  dependent censoring; log-rank test; multiple endpoints; semi-competing risk; time-dependent association

Mesh:

Year:  2017        PMID: 28120524      PMCID: PMC5533151          DOI: 10.1002/sim.7225

Source DB:  PubMed          Journal:  Stat Med        ISSN: 0277-6715            Impact factor:   2.373


  16 in total

1.  A convenient formula for sample size calculations in clinical trials with multiple co-primary continuous endpoints.

Authors:  Tomoyuki Sugimoto; Takashi Sozu; Toshimitsu Hamasaki
Journal:  Pharm Stat       Date:  2012 Mar-Apr       Impact factor: 1.894

2.  Testing and interval estimation for two-sample survival comparisons with small sample sizes and unequal censoring.

Authors:  Rui Wang; Stephen W Lagakos; Robert J Gray
Journal:  Biostatistics       Date:  2010-05-02       Impact factor: 5.899

3.  Landmark Estimation of Survival and Treatment Effect in a Randomized Clinical Trial.

Authors:  Layla Parast; Lu Tian; Tianxi Cai
Journal:  J Am Stat Assoc       Date:  2014-01-01       Impact factor: 5.033

4.  Using auxiliary variables for improved estimates of survival time.

Authors:  S W Lagakos
Journal:  Biometrics       Date:  1977-06       Impact factor: 2.571

5.  A logrank test-based method for sizing clinical trials with two co-primary time-to-event endpoints.

Authors:  Tomoyuki Sugimoto; Takashi Sozu; Toshimitsu Hamasaki; Scott R Evans
Journal:  Biostatistics       Date:  2013-01-10       Impact factor: 5.899

6.  A phase 3 trial of bevacizumab in ovarian cancer.

Authors:  Timothy J Perren; Ann Marie Swart; Jacobus Pfisterer; Jonathan A Ledermann; Eric Pujade-Lauraine; Gunnar Kristensen; Mark S Carey; Philip Beale; Andrés Cervantes; Christian Kurzeder; Andreas du Bois; Jalid Sehouli; Rainer Kimmig; Anne Stähle; Fiona Collinson; Sharadah Essapen; Charlie Gourley; Alain Lortholary; Frédéric Selle; Mansoor R Mirza; Arto Leminen; Marie Plante; Dan Stark; Wendi Qian; Mahesh K B Parmar; Amit M Oza
Journal:  N Engl J Med       Date:  2011-12-29       Impact factor: 91.245

7.  Tables of the number of patients required in clinical trials using the logrank test.

Authors:  L S Freedman
Journal:  Stat Med       Date:  1982 Apr-Jun       Impact factor: 2.373

8.  A stochastic model for censored-survival data in the presence of an auxiliary variable.

Authors:  S W Lagakos
Journal:  Biometrics       Date:  1976-09       Impact factor: 2.571

9.  Sample size determination for clinical trials with co-primary outcomes: exponential event times.

Authors:  Toshimitsu Hamasaki; Tomoyuki Sugimoto; Scott Evans; Takashi Sozu
Journal:  Pharm Stat       Date:  2012-10-19       Impact factor: 1.894

10.  A multi-state model for joint modelling of terminal and non-terminal events with application to Whitehall II.

Authors:  F Siannis; V T Farewell; J Head
Journal:  Stat Med       Date:  2007-01-30       Impact factor: 2.373

View more
  4 in total

Review 1.  Design, data monitoring, and analysis of clinical trials with co-primary endpoints: A review.

Authors:  Toshimitsu Hamasaki; Scott R Evans; Koko Asakura
Journal:  J Biopharm Stat       Date:  2017-10-30       Impact factor: 1.051

2.  Group-sequential logrank methods for trial designs using bivariate non-competing event-time outcomes.

Authors:  Tomoyuki Sugimoto; Toshimitsu Hamasaki; Scott R Evans; Susan Halabi
Journal:  Lifetime Data Anal       Date:  2019-04-12       Impact factor: 1.588

3.  Interim Monitoring for Futility in Clinical Trials with Two Co-primary Endpoints Using Prediction.

Authors:  Koko Asakura; Scott R Evans; Toshimitsu Hamasaki
Journal:  Stat Biopharm Res       Date:  2019-11-04       Impact factor: 1.452

4.  Sample size estimation using a latent variable model for mixed outcome co-primary, multiple primary and composite endpoints.

Authors:  Martina E McMenamin; Jessica K Barrett; Anna Berglind; James M S Wason
Journal:  Stat Med       Date:  2022-02-23       Impact factor: 2.497

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.